Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Exclusion Criteria

• •Female participants who are pregnant or breastfeeding.
• •Body Mass Index (BMI) \> 36 kg/m2.
• •Co-infected with hepatitis B virus or human immunodeficiency virus (HIV).
• •History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.
• •History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency.
• •Has one or more known primary or secondary causes of liver disease, other than hepatitis C
• •History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins, non-HCV viral hepatitis, gallstones or other etiologies
• •Donated blood or had significant blood loss 30 days prior to dosing